Literature DB >> 11550118

Antiretroviral therapy adherence and viral suppression in HIV-infected drug users: comparison of self-report and electronic monitoring.

J H Arnsten1, P A Demas, H Farzadegan, R W Grant, M N Gourevitch, C J Chang, D Buono, H Eckholdt, A A Howard, E E Schoenbaum.   

Abstract

To compare electronically monitored (MEMS) with self-reported adherence in drug users, including the impact of adherence on HIV load, we conducted a 6-month observational study of 67 antiretroviral-experienced current and former drug users. Adherence (percentage of doses taken as prescribed) was calculated for both the day and the week preceding each of 6 research visits. Mean self-reported 1-day adherence was 79% (median, 86%), and mean self-reported 1-week adherence was 78% (median, 85%). Mean MEMS 1-day adherence was 57% (median, 52%), and mean MEMS 1-week adherence was 53% (median, 49%). One-day and 1-week estimates were highly correlated (r>.8 for both measures). Both self-reported and MEMS adherence were correlated with concurrent HIV load (r=.43-.60), but the likelihood of achieving virologic suppression was greater if MEMS adherence was high than if self-reported adherence was high. We conclude that self-reported adherence is higher than MEMS adherence, but a strong relationship exists between both measures and virus load. However, electronic monitoring is more sensitive than self-report for the detection of nonadherence and should be used in adherence intervention studies.

Entities:  

Mesh:

Year:  2001        PMID: 11550118      PMCID: PMC2692641          DOI: 10.1086/323201

Source DB:  PubMed          Journal:  Clin Infect Dis        ISSN: 1058-4838            Impact factor:   9.079


  25 in total

1.  Mechanisms of virologic failure in previously untreated HIV-infected patients from a trial of induction-maintenance therapy. Trilège (Agence Nationale de Recherches sur le SIDA 072) Study Team).

Authors:  D Descamps; P Flandre; V Calvez; G Peytavin; V Meiffredy; G Collin; C Delaugerre; S Robert-Delmas; B Bazin; J P Aboulker; G Pialoux; F Raffi; F Brun-Vézinet
Journal:  JAMA       Date:  2000-01-12       Impact factor: 56.272

2.  Adherence to HAART in French HIV-infected injecting drug users: the contribution of buprenorphine drug maintenance treatment. The Manif 2000 study group.

Authors:  J P Moatti; M P Carrieri; B Spire; J A Gastaut; J P Cassuto; J Moreau
Journal:  AIDS       Date:  2000-01-28       Impact factor: 4.177

3.  Patient compliance and drug failure in protease inhibitor monotherapy.

Authors:  G F Vanhove; J M Schapiro; M A Winters; T C Merigan; T F Blaschke
Journal:  JAMA       Date:  1996-12-25       Impact factor: 56.272

4.  Improved survival among HIV-infected individuals following initiation of antiretroviral therapy.

Authors:  R S Hogg; K V Heath; B Yip; K J Craib; M V O'Shaughnessy; M T Schechter; J S Montaner
Journal:  JAMA       Date:  1998-02-11       Impact factor: 56.272

5.  Adherence to protease inhibitors, HIV-1 viral load, and development of drug resistance in an indigent population.

Authors:  D R Bangsberg; F M Hecht; E D Charlebois; A R Zolopa; M Holodniy; L Sheiner; J D Bamberger; M A Chesney; A Moss
Journal:  AIDS       Date:  2000-03-10       Impact factor: 4.177

6.  Sociodemographic and psychological variables influencing adherence to antiretroviral therapy.

Authors:  V Gordillo; J del Amo; V Soriano; J González-Lahoz
Journal:  AIDS       Date:  1999-09-10       Impact factor: 4.177

7.  Medication adherence in patients with HIV infection: a comparison of two measurement methods.

Authors:  K M Melbourne; S M Geletko; S L Brown; C Willey-Lessne; S Chase; A Fisher
Journal:  AIDS Read       Date:  1999-08

8.  Clinical manifestations and predictors of disease progression in drug users with human immunodeficiency virus infection.

Authors:  P A Selwyn; P Alcabes; D Hartel; D Buono; E E Schoenbaum; R S Klein; K Davenny; G H Friedland
Journal:  N Engl J Med       Date:  1992-12-10       Impact factor: 91.245

9.  Risk factors for human immunodeficiency virus infection in intravenous drug users.

Authors:  E E Schoenbaum; D Hartel; P A Selwyn; R S Klein; K Davenny; M Rogers; C Feiner; G Friedland
Journal:  N Engl J Med       Date:  1989-09-28       Impact factor: 91.245

10.  Adherence to zidovudine (AZT) among HIV-infected methadone patients: a pilot study of supervised therapy and dispensing compared to usual care.

Authors:  T L Wall; J L Sorensen; S L Batki; K L Delucchi; J A London; M A Chesney
Journal:  Drug Alcohol Depend       Date:  1995-03       Impact factor: 4.492

View more
  231 in total

1.  Suboptimal adherence associated with virological failure and resistance mutations to first-line highly active antiretroviral therapy (HAART) in Bangalore, India.

Authors:  Maria L Ekstrand; Anita Shet; Sara Chandy; Girija Singh; Ranjani Shamsundar; Vidya Madhavan; Shanmugam Saravanan; Elsa Heylen; Nagalingeswaran Kumarasamy
Journal:  Int Health       Date:  2011-03       Impact factor: 2.473

Review 2.  A proposal for quality standards for measuring medication adherence in research.

Authors:  Ann Bartley Williams; K Rivet Amico; Carol Bova; Julie A Womack
Journal:  AIDS Behav       Date:  2013-01

3.  Is average adherence to HIV antiretroviral therapy enough?

Authors:  David R Bangsberg; Steven G Deeks
Journal:  J Gen Intern Med       Date:  2002-10       Impact factor: 5.128

4.  Role of the Pharmacist in Caring for Patients with HIV/AIDS: Clinical Practice Guidelines.

Authors:  Alice Tseng; Michelle Foisy; Christine A Hughes; Deborah Kelly; Shanna Chan; Natalie Dayneka; Pierre Giguère; Niamh Higgins; Cara Hills-Nieminen; Jeff Kapler; Charles J L la Porte; Pam Nickel; Laura Park-Wyllie; Carlo Quaia; Linda Robinson; Nancy Sheehan; Shannon Stone; Linda Sulz; Deborah Yoong
Journal:  Can J Hosp Pharm       Date:  2012-03

Review 5.  Concordance of adherence measurement using self-reported adherence questionnaires and medication monitoring devices.

Authors:  Lizheng Shi; Jinan Liu; Yordanka Koleva; Vivian Fonseca; Anupama Kalsekar; Manjiri Pawaskar
Journal:  Pharmacoeconomics       Date:  2010       Impact factor: 4.981

6.  Psychiatric disorders and adherence to antiretroviral therapy among a population of HIV-infected adults in Nigeria.

Authors:  Olurotimi Adejumo; Bibilola Oladeji; Onoja Akpa; Kay Malee; Olusegun Baiyewu; Adesola Ogunniyi; Scott Evans; Baiba Berzins; Babafemi Taiwo
Journal:  Int J STD AIDS       Date:  2015-09-18       Impact factor: 1.359

7.  Superiority of directly administered antiretroviral therapy over self-administered therapy among HIV-infected drug users: a prospective, randomized, controlled trial.

Authors:  Frederick L Altice; Duncan Smith-Rohrberg Maru; R Douglas Bruce; Sandra A Springer; Gerald H Friedland
Journal:  Clin Infect Dis       Date:  2007-08-13       Impact factor: 9.079

8.  Adherence to antiretroviral therapy in a context of universal access, in Rio de Janeiro, Brazil.

Authors:  R H Remien; F I Bastos; V Terto Jnr; J C Raxach; R M Pinto; R G Parker; A Berkman; M A Hacker
Journal:  AIDS Care       Date:  2007-07

9.  A Randomized Controlled Trial of Rise, a Community-Based Culturally Congruent Adherence Intervention for Black Americans Living with HIV.

Authors:  Laura M Bogart; Matt G Mutchler; Bryce McDavitt; David J Klein; William E Cunningham; Kathy J Goggin; Bonnie Ghosh-Dastidar; Nikki Rachal; Kelsey A Nogg; Glenn J Wagner
Journal:  Ann Behav Med       Date:  2017-12

10.  The information-motivation-behavioral skills model of ART adherence in a Deep South HIV+ clinic sample.

Authors:  K Rivet Amico; William Barta; Deborah J Konkle-Parker; Jeffrey D Fisher; Deborah H Cornman; Paul A Shuper; William A Fisher
Journal:  AIDS Behav       Date:  2007-09-18
View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.